We are the collective of our combined knowledge base.
Our team has a breadth of expertise, and together, we attack cancer from every direction.
"If you want to go fast, go alone; if you want to go far, go together."
Join our team.“I'm honored to be working with the Tempus team as they advance innovative tools for personalizing patient care and empower providers with information that can help them make better and more informed treatment decisions for their patients.”
Scott Gottlieb, MD, Scientific Advisor
“As a surgical oncologist, I have worked to reduce racial, ethnic and gender health care disparities throughout my career. Tempus is a leader in the field of data-driven medicine, and I am excited to work with their team to further enhance patient outcomes for individuals of all backgrounds and from all communities.”
Wayne A. I. Frederick, MD, MBA, Charles R. Drew Professor of Surgery
“We are thrilled to have led an investment in Tempus... Given NEA's long and successful history investing in the intersection of technology and life science, we felt like the perfect strategic partner given Tempus' mission to help doctors personalize care by collecting and analyzing large volumes of data.”
Peter Barris, Chairman & General Partner, New Enterprise Associates
“Having spent my entire career at the forefront of emerging technologies, it’s exciting to see how healthcare is finally embracing the very technologies that have transformed so many other industries. This is a space that is near and dear to me, and I'm excited to be a part of Tempus as they seek to bring big data, artificial intelligence and advanced molecular analysis to those suffering with cancer and other life threatening diseases.”
Ted Leonsis, Cofounder & Partner, Revolution Growth
“Nowhere is technology more desperately needed than in healthcare. As a country, we spend over three trillion dollars annually. We have a social and economic imperative to improve our healthcare system: to make it better, more accessible, and more effective. I'm thrilled to have invested in Tempus and their team of innovators who are obsessed with developing breakthroughs in how we treat diseases.”
John Doerr, Chairman, Kleiner Perkins